在医保准入评估方面,我国正逐步适用以联合用药方案为评估单元的国际主流模式,但仍面临不少难题和挑战。本文结合国际经验与我国实际需求,重点解决 “联合方案价值如何体现”及“单药价格如何分配”两个问题,提出优化参照药物选择、增加评估维度、灵活调整阈值,并明确价格分配机制,为优化我国联合用药准入评估提供参考。
Abstract
National Healthcare Security Administration is gradually developing a method consistent with the international mainstream that combination therapies are evaluated as one unit, but there are still many difficulties, challenges. Combining international experience with the actual needs of China, this paper focuses on solving two problems of "how to embody the value of combination therapy", "how to distribute the price of individual drugs in combination therapy". Furthermore, the paper also proposes suggestions of optimizing the selection of comparators, increasing the evaluation dimensions, flexibly adjusting the threshold, clarifying the price distribution mechanism, which provides reference for improving the access evaluation model of combination therapy in China
关键词
联合用药 /
临床价值 /
价格分配
Key words
combination therapy /
clinical value /
price distribution
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] He B, Lu C, Zheng G, et al.Combination therapeutics in complex diseases[J]. Journal of Cellular & Molecular Medicine, 2016.
[2] Ascierto Paolo A, Marincola Francesco M.Combination therapy: the next opportunity and challenge of medicine[J]. Journal of translational medicine,2011,9(1).
[3] Boshuizen J, Peeper D S .Rational Cancer Treatment Combinations: An Urgent Clinical Need[J]. Molecular Cell, 2020, 78(6):1002-1018.
[4] Maly JJ, Macrae ER. Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy,Progression Free Survival[J]. Breast Cancer (Auckl), 2014 May 12;8:81-8.
[5] Mokhtari R B, Homayouni T S, Baluch N, et al.Combination therapy in combating cancer[J]. Oncotarget, 2017, 8(23).
[6] Sica, Domenic A .Rationale for combination therapy in the treatment of hypertension[J]. Journal of Renin-Angiotensin-Aldosterone System, 2002, 3(2):63-65.
[7] Wei Sun,Philip E. Sanderson,Wei Zheng.Drug combination therapy increases successful drug repositioning[J].Drug Discovery Today,2016,21(7).
[8] 国家药品监督管理局药品审评中心.关于发布《以临床价值为导向的抗肿瘤药物临床研发指导原则》的通告(2021年第46号)[EB/OL]. [2022-08-14].https://www.cde.org.cn/main/news/viewInfoCommon/ef7bfde96c769308ad080bb7ab2f538e.
[9] Pharmaceutical-technology. Reimbursement outcomes for combination therapies in breast cancer[EB/OL].[2022-08-14]. https://www.pharmaceutical-technology.com/pricing-and-market-access/reimbursement-outcomes-combination-therapies-breast-cancer-html/.
[10] Xia & He.谈谈在临床试验中如何设计联合用药(系列之一)[EB/OL]. [2022-08-14].https://www.xiahepublishing.com/2475-7543/MRP-2021-010.
[11] Latimer N, Pollard D .Pre-read document 1 : challenges in valuing and paying for combination regimens in oncology. 2019.
[12] Briggs A H, Doyle A, Schneider J, et al. An Attribution of Value Framework for Combination Therapies, 2021[C].
[13] Latimer N R, Towse A, Henshall C .Not cost-effective at zero price: valuing and paying for combination therapies in cancer[J]. Expert Review of Pharmacoeconomics & Outcomes Research, 2021.
[14] NICE. Technology appraisal guidance: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer(Published: 07 March2018). [EB/OL]. [2022-08-14]. https://www.nice.org.uk/guidance/ta509.
[15] Australian Government-Department of Health. PERTUZUMAB, 420 mg/14 mL injection, 1 x 14 mL vial Perjeta®, Roche Products Pty Ltd.[EB/OL]. [2022-08-14]. https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2014-03/pertuzumab-psd-03-2014.pdf.
[16] Australian Government-Department of Health. Public Summary Document - July2018 PBAC Meeting: Nivolumab and Ipilimumab [EB/OL]. [2022-08-14]. https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2018-07/files/nivolumab-and-ipilimumab-melanoma-psd-july-2018.pdf.
[17] Scottish Medicines Consortum.Medicines advice:carfilzomib (Kyprolis) . [EB/OL].[2022-08-14]. https://www.scottishmedicines.org.uk/medicines-advice/carfilzomib-kyprolis-fullsubmission-124217/.
[18] Dd A, Jyb B, Lpg C .Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology - ScienceDirect[J]. Health Policy, 2019, 123( 12):1230-1236.
[19] Lakdawalla D N, Doshi J A, Garrison L P, et al.Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3][J]. Value in Health, 2018, 21(2):131-139.
[20] Shafrin J, Dennen S, Pednekar P, et al.For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports[J]. Journal of Managed Care & Specialty Pharmacy, 2021:1-10.
[21] Angst D C, Tepekule B, Sun L, et al.Comparing treatment strategies to reduce antibiotic resistance in an in vitro epidemiological setting[J]. Proceedings of the National Academy of Sciences, 2021, 118(13).
[22] Superbugs II: how should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance?[J]. Health Economics, 2002, 11(7):637.
[23] Morton A, Colson A, Leporowski A, et al.How Should the Value Attributes of Novel Antibiotics Be Considered in Reimbursement Decision Making?[J]. MDM Policy, Practice, 2019, 4(2).
[24] Prząda-Machno P, Marzec M, Borowiack E, Nowotarska A, Jarosz J, Szczuka A, et al.Add-on therapy in breast cancer—probability of cost-effectiveness in economic analyses. Value Health. 2017;20(9):A445.
[25] Solaman D A, Walker A, Alba S, et al.PP40 HTA Evaluations Of Combination Drugs: Positive Reimbursement Solutions[J]. International Journal of Technology Assessment in Health Care, 2018, 34(S1):80-81.
[26] NICE. Guide to the methods of technology appraisal2013 Process and methods [PMG9] [EB/OL]. [2022-08-14]. https://www.nice.org.uk/process/pmg9/chapter/the-appraisal-of-the-evidence-and-structured-decision-making.
[27] NICE. Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma Technology appraisal guidance [TA396] [EB/OL].[2022-08-14].https://www.nice.org.uk/guidance/ta396.
[28] NICE. Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma [EB/OL].[2022-08-15]. https://www.nice.org.uk/guidance/ta562.
基金
国家医疗保障局《药品医保支付标准制定指导规则研究》项目
